SCHEMBL1640568

SCHEMBL1640568

CCc1nc(-c2cccc(NC(=O)c3c(F)cccc3F)c2)c(-c2ccnc(Cl)n2)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 1/20 0.49
MAPK14 Q16539 14/20 0.48
EGFR P00533 3/20 0.45
IKBKB O14920 1/20 0.45
MAPK13 O15264 1/20 0.45
PRKD3 O94806 1/20 0.45
MAP4K4 O95819 1/20 0.45
MAPK1 P28482 1/20 0.45
FLT4 P35916 1/20 0.45
KDR P35968 1/20 0.45
FRK P42685 1/20 0.45
MAPK8 P45983 1/20 0.45
MAPK9 P45984 1/20 0.45
CSNK1A1 P48729 1/20 0.45
CSNK1D P48730 1/20 0.45
CSNK1E P49674 1/20 0.45
MAPK12 P53778 1/20 0.45
CSNK1G2 P78368 1/20 0.45
PTK6 Q13882 1/20 0.45
ERBB4 Q15303 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1641468 0.92 BRAF (0.48) BRAFMAPK14EGFRPRKD3MAP4K4
SCHEMBL1641904 0.88 BRAF (0.51) BRAFMAPK14EGFRTP53MAPT
SCHEMBL1641688 0.88 BRAF (0.48) BRAFEGFRPRKD3MAP4K4KDR
SCHEMBL1641905 0.88 BRAF (0.45) BRAFMAPK14EGFRPRKD3MAP4K4
SCHEMBL1640498 0.87 BRAF (0.49) BRAFEGFRPRKD3MAP4K4MAPK1
SCHEMBL1641783 0.87 BRAF (0.45) BRAFMAPK14EGFRPRKD3MAP4K4
SCHEMBL1641081 0.87 BRAF (0.49) BRAFEGFRPRKD3MAP4K4KDR
SCHEMBL1639294 0.86 BRAF (0.49) BRAFEGFRPRKD3MAP4K4MAPK1
SCHEMBL1642030 0.86 BRAF (0.64) BRAFEGFRTP53MAPTERBB2
SCHEMBL1641100 0.86 BRAF (0.54) BRAFEGFRPRKD3MAP4K4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
EP-2231625-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-29 EP disclosed
WO-2009076140-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-18 WO disclosed
WO-2009076140-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors PDXK, MAP3K1, MAP4K2 BRAF 151/4885MAPK14 312/4885EGFR 478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.